Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intranasal dexmedetomidine versus midazolam for pediatric dental sedation: a pooled analysis of clinical trials.

Frontiers in medicine·2026
Same author

Machine learning-optimized charge transfer nanocrystals for synergistic NIR photothermal therapy, ferroptosis, and electrochemical detection of breast cancer.

Colloids and surfaces. B, Biointerfaces·2026
Same author

Decoding orientation serial dependence from V1/V2 population responses using a cross-attention transformer.

The Journal of neuroscience : the official journal of the Society for Neuroscience·2026
Same author

NCF1 aggravates cerebral ischemia-reperfusion injury by amplifying NOX2-Dependent oxidative stress and inflammatory responses.

Biochemical and biophysical research communications·2026
Same author

Prenatal corticosteroid use improves the severity and complications of necrotizing enterocolitis in preterm infants: a retrospective multicenter clinical study in China.

PeerJ·2026
Same author

Effectiveness of non-pharmacological interventions for post-stroke depression: protocol for an umbrella review of systematic reviews and meta-analyses.

Systematic reviews·2026

Related Experiment Video

Updated: Jul 17, 2026

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Low-dose docetaxel reprograms CAR T cells for enhanced solid tumor immunity.

Songshan Zhu1,2, Jun Yin3, Xin Fu1

  • 1Guangdong Provincial Key Laboratory of Medical Immunology and Molecular Diagnostics, The First Dongguan Affiliated Hospital, School of Medical Technology, Guangdong Medical University, Dongguan, People's Republic of China.

Journal of Experimental & Clinical Cancer Research : CR
|July 16, 2026
PubMed
Summary

Low-dose docetaxel reprograms CAR T cells to overcome solid tumor barriers. This priming enhances T cell potency and persistence, offering a scalable chemotherapy-immunotherapy synergy for cancer treatment.

Keywords:
CAR T cellDocetaxelExosomesImmunotherapySolid tumorTumor microenvironment

More Related Videos

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Generation and Functional Verification of Hypoxia-Sensitive Chimeric Antigen Receptor-T Cells
09:12

Generation and Functional Verification of Hypoxia-Sensitive Chimeric Antigen Receptor-T Cells

Published on: June 14, 2024

Related Experiment Videos

Last Updated: Jul 17, 2026

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Generation and Functional Verification of Hypoxia-Sensitive Chimeric Antigen Receptor-T Cells
09:12

Generation and Functional Verification of Hypoxia-Sensitive Chimeric Antigen Receptor-T Cells

Published on: June 14, 2024

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • CAR T cell therapy faces challenges in solid tumors, including stromal barriers, T cell exhaustion, and limited persistence.
  • Low-dose docetaxel shows potential as an immunomodulatory primer to enhance CAR T cell function.
  • Host lymphocyte reserve influences docetaxel treatment efficacy, suggesting an immunological mechanism.

Purpose of the Study:

  • To investigate the immunomodulatory effects of low-dose docetaxel on CAR T cells.
  • To explore docetaxel's potential to overcome solid tumor barriers and enhance CAR T cell efficacy.
  • To characterize the cellular and molecular changes induced by docetaxel priming.

Main Methods:

  • Assessed sub-cytotoxic docetaxel concentrations in human T cells and CAR T cells using phenotypic, transcriptional, and functional assays.
  • Characterized docetaxel-induced changes in secretory profiles and extracellular vesicle cargo.
  • Evaluated efficacy in 3D spheroids and xenograft models.

Main Results:

  • Docetaxel priming induced a 'Metabolic-Cycle Uncoupling' state, enhancing cytotoxic effector potency and memory traits while constraining proliferation.
  • Priming upregulated Rab27-dependent exosome biogenesis, reduced exhaustion markers (PD-1, CD57), and enriched cytotoxic ligands (FasL, TRAIL) and homing receptors.
  • Primed CAR T cells demonstrated improved antitumor efficacy, stromal remodeling, host T cell activation, and bystander tumor cell killing via secreted exosomes.

Conclusions:

  • Docetaxel priming offers a non-genetic, scalable strategy compatible with existing manufacturing processes.
  • This approach enhances CAR T cell performance against solid tumor barriers in preclinical models.
  • Chemotherapy-immunotherapy synergies hold significant potential for improving cancer treatment outcomes.